Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

ABSTRACT:

Importance

Patients with oligometastatic non-small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for the use of immunotherapy exists in a minimal residual disease state.

Objective

To evaluate whether the addition of pembrolizumab after LAT improves outcomes for patients with oligometastatic NSCLC.

Design, setting, and participants

This single-arm phase 2 trial of pembrolizumab therapy was performed from February 1, 2015, through September 30, 2017, at an academic referral cancer center. The 51 eligible patients enrolled had oligometastatic NSCLC (≤4 metastatic sites) and had completed LAT to all kno

SUBMITTER: Bauml JM 

PROVIDER: S-EPMC6624820 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature